ELIXA trial shows CV safety of lixisenatide
LONDON, UK - 30 August, 2015: In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.
The study, presented today at ESC Congress 2015, "demonstrates the cardiovascular safety of lixisenatide", reported Eldrin F. Lewis, MD, MPH, a member of the ELIXA trial's executive committee, a physician in the Cardiovascular Medicine Division at Brigham ...

